Zevra Therapeutics, Inc. (ZVRA) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Zevra Therapeutics, Inc. (ZVRA:NASDAQ), powered by AI.

Current Price
$12.65
P/E Ratio
8.4
Market Cap
700M
Sector
Healthcare
What is the Zevra Therapeutics, Inc. stock price forecast?

Zevra Therapeutics, Inc. is currently trading at $12.65. View real-time AI analysis on Alpha Lenz.

What is Zevra Therapeutics, Inc. insider trading activity?

View the latest insider trading data for Zevra Therapeutics, Inc. on Alpha Lenz.

What is Zevra Therapeutics, Inc.'s P/E ratio?

Zevra Therapeutics, Inc.'s P/E ratio is 8.4.

Zevra Therapeutics, Inc.

NASDAQ · ZVRA
$12.65+0.10(+0.80%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Zevra Therapeutics, Inc.'s future dividend policy...
Alpha Chat Insight

Zevra Therapeutics, Inc. trades at a P/E of 8.4 (undervalued) with strong ROE of 85.7%. 3Y revenue CAGR of 118.8% highlights clear growth momentum.

Ask for details

Company Overview

Zevra Therapeutics Inc. is a pharmaceutical company specializing in the development and commercialization of innovative therapies. Its primary focus is on addressing unmet medical needs across a range of therapeutic areas. Zevra Therapeutics engages in delivering transformative medical solutions for patients through a robust pipeline of candidate drugs. The company places significant emphasis on rare and orphan diseases, seeking to bring life-changing treatments to those often overlooked in the broader medical landscape. Notable features of Zevra Therapeutics include its commitment to leveraging scientific expertise and advanced research methodologies to develop novel therapies. The company collaborates with a network of research institutions, healthcare professionals, and regulatory bodies to ensure the successful translation of scientific discovery into practical treatments. In the market, Zevra Therapeutics holds a pivotal role in contributing to pharmaceutical innovation and enhancing patient outcomes. Its efforts are vital in pushing the boundaries of traditional treatment paradigms, thereby fostering advancements in the medical field. With a strategic focus on impactful therapeutic areas, Zevra Therapeutics is positioned as a key contributor to the dynamic landscape of the life sciences industry.

CEOMr. Neil F. McFarlane
SectorHealthcare
IndustryBiotechnology
Employees59

Company Statistics

FY 2025

Profile

$699.69MMarket Cap
$106.47MRevenue
0.00Shares Out
59Employees

Margins

84.52%Gross
6.36%EBITDA
-3.98%Operating
81.41%Pre-Tax
78.17%Net

Valuation

8.41P/E
4.52P/B
6.57EV/Sales
103.52EV/EBITDA
-287.58P/FCF

Growth (CAGR)

118.83%Rev 3Yr
51.62%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

35.96%ROA
85.66%ROE
40.90%ROIC

Financial Health

$62.41MCash & Cash Equivalents
$67.67MNet Debt
84.10%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Zevra Therapeutics, Inc. (ticker: ZVRA) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 59 employees. Market cap is $700M.

The current price is $12.65 with a P/E ratio of 8.41x and P/B of 4.52x.

ROE is 85.66% and operating margin is -3.98%. Annual revenue is $106M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Zevra Therapeutics, Inc. (ZVRA) Stock Forecast 2026 $12.65 — Price, Financials & Analyst Targets | Alpha Lenz